Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
3 Top Earnings Acceleration Stocks to Buy for 2H25
04:01pm, Tuesday, 08'th Jul 2025
Yext, Agenus and NCR Voyix show accelerating earnings growth, making them standout picks for the second half.
Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
08:55am, Monday, 07'th Jul 2025
LEXINGTON, Mass.--(BUSINESS WIRE)-- #CancerCare--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
10:56am, Thursday, 19'th Jun 2025
After reaching an important support level, Agenus Inc. (AGEN) could be a good stock pick from a technical perspective. AGEN recently experienced a "golden cross" event, which saw its 50-day simple mov
LEXINGTON, Mass. & SAN FRANCISCO--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN) a leader in immuno-oncology innovation and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a
Agenus Announces Virtual Annual Shareholders Meeting
01:30pm, Tuesday, 10'th Jun 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader in immuno-oncology innovation, today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET o
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
02:38pm, Wednesday, 04'th Jun 2025
On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s AGEN U.
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade
11:01am, Wednesday, 04'th Jun 2025
The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd. (NSE
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
07:30am, Friday, 30'th May 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeti
Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
03:09pm, Friday, 23'rd May 2025
I remain cautiously optimistic about Agenus, driven by BOT/BAL's strong clinical data and cost-reduction efforts, but maintain a speculative 2/5 conviction rating. The BOT/BAL program shows promising
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
09:51am, Monday, 19'th May 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed t
Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025
10:40am, Thursday, 15'th May 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensil
Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript
02:46pm, Monday, 12'th May 2025
Agenus Inc. (NASDAQ:AGEN ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Zack Armen - Head of Investor Relations Garo Armen - Chairman and CEO Steven O'Day - Chief Medi
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
09:51am, Monday, 12'th May 2025
Agenus (AGEN) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $3.04 per share a year ago.
Agenus Reports Q1 2025 Financial Results and Key Business Updates
07:30am, Monday, 12'th May 2025
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter o
